DDInter469 DDInter1763
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dalfopristin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Dalfopristin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Temsirolimus (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)